Nascent Stem Cell Company Raises Ethical and Medical Issues
By Bernadette Tansey,
San Francisco Chronicle
| 10. 29. 2007
A San Carlos startup is offering to create "personalized" stem cells from the spare embryos of fertility clinic clients on the chance that the cells, frozen and stored away, may some day help a family member benefit from medical breakthroughs.
The novel business plan of StemLifeLine Inc. - which started promoting its service to fertility patients earlier this year as "insurance for the future" - set off a flash fire of protest from stem cell research opponents and supporters alike.
The outcry from anti-abortion groups wasn't surprising. StemLifeLine derives stem cells from very early stage human embryos, which are destroyed in the process. Opponents of the research see this as the moral equivalent of killing a child. This belief is the basis of the Bush administration's limits on federal funding of embryonic stem cell research.
But some of the most fervent denunciations of StemLifeLine came from vigorous supporters of embryonic stem cell research. Two Stanford University critics aired their complaints in newspaper editorial pages. A prominent Stanford ethicist challenged UC San Francisco scientists who are advisers of the company to...
Related Articles
By Miryam Naddaf, Nature | 09.21.2026
A wave of epigenetic therapies is offering hope as ways to cure chronic hepatitis B — a lingering liver infection that is caused by the hepatitis B virus (HBV) and affects more than 250 million people around the world. Currently...
By Karen Weintraub, Endpoints News | 09.16.2026
To better understand certain neuropsychiatric disorders, researchers at Stanford University have bred rodents that lack a cortex and hippocampus and then replaced those missing brain cells with human ones.
The altered mice, a scientific first, provided insights that would not...
By Ryan Cross, Endpoints News | 09.02.2026
The deaths of two children who received CRISPR therapies in China have rattled scientists who work on similar genetic medicines in the US, adding new fuel to a yearslong debate about the danger of the gene therapy field’s most-used delivery...
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...